Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

179 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany.
Pfisterer J, Du Bois A, Bentz EK, Kommoss F, Harter P, Huober J, Schmalfeldt B, Burchardi N, Arnold N, Hilpert F. Pfisterer J, et al. Among authors: kommoss f. Int J Gynecol Cancer. 2009 Jan;19(1):109-15. doi: 10.1111/IGC.0b013e3181991a7c. Int J Gynecol Cancer. 2009. PMID: 19258951 Clinical Trial.
The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary: A Subanalysis of the Prospective Multicenter ROBOT Study.
Fotopoulou C, Sehouli J, Ewald-Riegler N, de Gregorio N, Reuss A, Richter R, Mahner S, Kommoss F, Schmalfeldt B, Fehm T, Hanker L, Wimberger P, Canzler U, Pfisterer J, Kommoss S, Hauptmann S, du Bois A; ROBOT investigators. Fotopoulou C, et al. Among authors: kommoss f, kommoss s. Int J Gynecol Cancer. 2015 Sep;25(7):1248-52. doi: 10.1097/IGC.0000000000000476. Int J Gynecol Cancer. 2015. PMID: 25978292
Survival benefit for patients with advanced-stage transitional cell carcinomas vs. other subtypes of ovarian carcinoma after chemotherapy with platinum and paclitaxel.
Kommoss F, Kommoss S, Schmidt D, Trunk MJ, Pfisterer J, du Bois A; Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom. Kommoss F, et al. Among authors: kommoss s. Gynecol Oncol. 2005 Apr;97(1):195-9. doi: 10.1016/j.ygyno.2004.12.047. Gynecol Oncol. 2005. PMID: 15790458 Clinical Trial.
Histological grading in a large series of advanced stage ovarian carcinomas by three widely used grading systems: consistent lack of prognostic significance. A translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol).
Kommoss S, Schmidt D, Kommoss F, Hedderich J, Harter P, Pfisterer J, du Bois A. Kommoss S, et al. Among authors: kommoss f. Virchows Arch. 2009 Mar;454(3):249-56. doi: 10.1007/s00428-009-0725-y. Epub 2009 Jan 27. Virchows Arch. 2009. PMID: 19172293
Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes.
Kommoss S, Winterhoff B, Oberg AL, Konecny GE, Wang C, Riska SM, Fan JB, Maurer MJ, April C, Shridhar V, Kommoss F, du Bois A, Hilpert F, Mahner S, Baumann K, Schroeder W, Burges A, Canzler U, Chien J, Embleton AC, Parmar M, Kaplan R, Perren T, Hartmann LC, Goode EL, Dowdy SC, Pfisterer J. Kommoss S, et al. Among authors: kommoss f. Clin Cancer Res. 2017 Jul 15;23(14):3794-3801. doi: 10.1158/1078-0432.CCR-16-2196. Epub 2017 Feb 3. Clin Cancer Res. 2017. PMID: 28159814 Free PMC article. Clinical Trial.
Cellular DNA content and survival in advanced ovarian carcinoma.
Pfisterer J, Kommoss F, Sauerbrei W, Renz H, du Bois A, Kiechle-Schwarz M, Pfleiderer A. Pfisterer J, et al. Among authors: kommoss f. Cancer. 1994 Nov 1;74(9):2509-15. doi: 10.1002/1097-0142(19941101)74:9<2509::aid-cncr2820740919>3.0.co;2-f. Cancer. 1994. PMID: 7923008
179 results